Signal Management Governance

Signal management is not only a scientific process. It is also a governance process because important safety conclusions must be made by people with appropriate authority, escalated when necessary, documented clearly and translated into action across the pharmacovigilance system.

Purpose and Regulatory Framework

EU signal management is governed by Directive 2001/83/EC, Regulation (EC) No 726/2004, Commission Implementing Regulation (EU) No 520/2012 as amended, and GVP Module IX — Signal management. The wider quality-system and QPPV framework is described in GVP Module I.

These sources establish responsibilities for effective signal management, but they do not prescribe a universal corporate governance architecture. An MAH may use formal committees, product teams, delegated decision makers or hybrid arrangements. The model is acceptable only if it reliably produces scientifically sound, timely and traceable decisions.

Governance Across the Signal Lifecycle

Governance should support the whole lifecycle:

detection → validation → prioritisation → assessment → decision → action → follow-up or closure.

For each stage, the organisation should know:

• who performs the activity;
• who can make the decision;
• when additional expertise is required;
• when escalation is required;
• how the decision is recorded; and
• which downstream processes must be informed.

A governance model is weak when responsibility becomes ambiguous at interfaces—for example, between signal assessment and regulatory implementation.

Responsibility and Decision Rights

Responsibility should be explicit enough that staff can answer practical questions such as:

• Who can close a potential signal after validation?
• Who can decide that a full assessment is needed?
• Who owns the scientific conclusion?
• Who determines whether regulatory advice or notification is needed?
• Who ensures an RMP or product-information impact assessment is performed?
• Who escalates an issue to the QPPV?

The answer need not be the same role for every product or every level of signal significance. Proportionality is important.

Governance Should Match Risk

Low-complexity routine decisions may be managed within specialist teams. A signal with potential public-health consequences, major uncertainty or significant regulatory implications may require broader multidisciplinary review and senior pharmacovigilance visibility.

Governance should therefore scale with:

• clinical seriousness;
• strength and uncertainty of evidence;
• exposed population;
• vulnerability of affected patients;
• potential impact on benefit-risk;
• regulatory interest; and
• complexity of the action required.

This principle is more useful than requiring every signal to pass through the same committee sequence.

Escalation

Escalation is the mechanism that prevents important information from remaining at the wrong organisational level.

An effective escalation process identifies:

• the types of issue that require escalation;
• the recipient or governance level;
• the urgency of the escalation;
• what supporting information should accompany it; and
• how the decision and subsequent action are recorded.

Operational triggers can be defined, but they should support rather than replace scientific judgement.

Committees and Governance Forums

Formal committees can be useful when a signal requires multidisciplinary challenge or senior decision-making. However, the committee is a means of governance, not the regulatory objective itself.

A committee-based model should avoid two extremes. At one extreme, no one has clear authority and important issues circulate between functions. At the other, every minor decision is forced through several governance layers, creating delay without adding scientific value.

The companion article Signal Management Committees examines committee design in detail. The broader governance principle is that the right expertise and authority should be applied at the right point in the lifecycle.

QPPV Oversight

The QPPV should have sufficient visibility of significant signal matters to maintain oversight of the pharmacovigilance system. That does not require personal review of every screening output, validation decision or signal closure.

A governance framework should ensure that the QPPV can:

• receive timely escalation of important safety concerns;
• understand unresolved scientific uncertainty;
• challenge important conclusions or proposed actions;
• obtain supporting evidence when needed;
• see significant signal-management quality problems; and
• understand whether resulting regulatory and risk-management actions have been implemented.

Oversight fails when QPPV awareness depends entirely on informal relationships or discretionary communication.

Integration With Benefit-Risk and Risk Management

Signal decisions have consequences across the pharmacovigilance system. Governance should therefore connect signal management with:

• RMP safety concerns and pharmacovigilance activities;
• PSUR/PBRER conclusions;
• product-information changes;
• risk-minimisation measures;
• PASS or other data-generation plans;
• safety communications; and
• regulatory interactions.

A signal can be scientifically closed while leaving downstream actions open. Governance should keep those distinctions visible.

Regulatory Change Management

Governance must also respond when the regulatory framework changes. The 2025 amendment to the EU pharmacovigilance implementing regulation and EMA's conclusion of the MAH EudraVigilance signal-detection pilot are a practical example.

A controlled organisation should assess:

• which SOPs and work instructions are affected;
• whether system configurations or scheduled activities must change;
• whether vendor contracts or responsibilities require amendment;
• whether staff need targeted training; and
• whether historical metrics or dashboards need reinterpretation.

A current governance process should not continue obsolete regulatory activities simply because they are embedded in legacy procedures.

Outsourcing and Affiliate Interfaces

Signal-management responsibilities may cross vendors, affiliates, licence partners and global functions. Governance should make these interfaces explicit.

Important questions include:

• Who detects and communicates observations at each interface?
• Which party performs validation or assessment?
• How rapidly must important information move between parties under the applicable agreement?
• Which organisation makes the final MAH decision?
• How are divergent conclusions handled?
• Can the MAH access the evidence necessary to defend the decision?

Contracts and safety-data exchange agreements should support the operating model rather than substitute for active oversight.

Quality-System Interface

Signal governance should connect with deviation, CAPA, audit, training and change-control processes.

Examples of system-level issues include:

• recurring overdue assessments;
• inconsistent validation criteria;
• incomplete signal records;
• recurring vendor failures;
• inappropriate access or workflow controls;
• disconnects between signal decisions and RMP or labelling actions; and
• obsolete procedures after regulatory change.

These issues should be assessed as quality-system risks, not merely treated as isolated signal-record defects.

Governance Evidence

Useful evidence may include:

• controlled procedures and role descriptions;
• signal workflow histories;
• decision records or meeting minutes;
• escalation records;
• QPPV governance reports;
• downstream action trackers;
• vendor performance and quality records;
• deviations and CAPAs; and
• change-control records for methodology or regulatory updates.

The evidence should tell one coherent story about how the system makes and implements decisions.

Illustrative Governance Failure Modes

The following are hypothetical failure modes, not reported inspection findings.

Inspection Questions

An inspector or internal auditor may ask:

1. Who can make each major signal decision?
2. How is authority delegated and documented?
3. What requires escalation and what does not?
4. How are urgent issues handled outside routine governance cycles?
5. How does the QPPV obtain visibility of significant matters?
6. How are conflicting expert views documented and resolved?
7. How are outsourced activities incorporated into MAH governance?
8. How do signal conclusions enter the RMP, PSUR/PBRER and product-information processes?
9. How are overdue or incomplete actions monitored?
10. How were the 2025–2026 EudraVigilance changes incorporated into the system?

Recommended Governance Review Checklist

The following is recommended operational practice, not an EMA-mandated template.

• Are roles and decision rights explicit?
• Does governance scale with risk and complexity?
• Are escalation routes usable in urgent situations?
• Is multidisciplinary expertise available when needed?
• Is QPPV visibility proportionate to significance?
• Are records sufficient to reconstruct rationale and action?
• Are vendors, affiliates and partners integrated into the same decision framework?
• Are quality-system issues escalated beyond individual signal records?
• Are downstream actions reconciled across regulatory documents?
• Is regulatory change translated promptly into procedures, systems and training?

Key Takeaways

Signal-management governance converts scientific evaluation into accountable, traceable and implementable decisions.

The EU framework requires an effective signal-management system but does not prescribe a universal committee hierarchy, quorum model or approval chain.

Governance should be proportionate. Routine decisions can remain operational; important, uncertain or high-impact matters require broader challenge and escalation.

QPPV oversight should be designed into the system rather than depend on informal communication.

The strongest governance model connects signal decisions to downstream benefit-risk, RMP, product-information and quality-system actions and remains adaptable when the regulatory framework changes.

References

1. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module IX — Signal management (Rev. 1). EMA/827661/2011 Rev. 1.
2. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module I — Pharmacovigilance systems and their quality systems. EMA/541760/2011.
3. European Medicines Agency. Questions and answers on signal management. EMA/261758/2013 Rev. 5, updated 20 January 2026.
4. European Medicines Agency. Signal management. Current EMA procedural page.
5. European Union. Commission Implementing Regulation (EU) No 520/2012, as amended by Commission Implementing Regulation (EU) 2025/1466.
6. European Union. Directive 2001/83/EC, as amended.
7. European Union. Regulation (EC) No 726/2004, as amended.

Regulatory Note

This article distinguishes regulatory requirements for effective signal management and pharmacovigilance-system oversight from company-specific governance structures. Standing committees, quorum rules, fixed escalation matrices and universal QPPV approvals are organisational controls rather than general EU legal requirements. Current EMA guidance should be checked because Module IX Rev. 1 remains published while revision is planned following the 2025 implementing-regulation amendments.